According to most of the mainstream guidelines, angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are generally recommended for all patients with acute coronary syndrome (ACS) unless contraindicated as they could effectively reduce the mortality and risk of recurrent myocardial infarction (MI), which has been demonstrated in many randomized clinical trials (Amsterdam et al., 2014; Ibanez et al., 2018; O'Gara et al., 2013; Collet et al., 2021; Bangalore et al., 2017). Here, ACE is linked to acute coronary syndrome.